Treatment strategies

CROI 2022: Dolutegravir plus recycled tenofovir rather than switch to AZT: public health approach to second-line ART

2 May 2022. Related: Conference reports, Antiretrovirals, Treatment strategies.

EACS 2021: a call for collaborations and for both HIV and COVID-19

31 October 2021. Related: Conference reports, Treatment strategies, HIV prevention and transmission.

CROI 2021: Dolutegravir with recycled tenofovir and lamivudine performs well second-line: primary results from the NADIA trial

12 March 2021. Related: Conference reports, Treatment strategies.

Baseline NNRTI resistance linked to poorer response to first-line dolutegravir in the ADVANCE study

22 January 2021. Related: Treatment strategies, Resistance.

Dolutegravir non-inferior to efavirenz at week 96 in the NAMSAL study but associated with substantial weight gain

28 August 2020. Related: Conference reports, Treatment strategies.

Switching from efavirenz- to dolutegravir-based ART second-line achieved good rates of suppression: first results from the VISEND study

28 August 2020. Related: Conference reports, Treatment strategies.

Early drugs being studied for COVID-19

27 March 2020. Related: Treatment strategies, COVID-19: investigational drugs, COVID-19.

Four days on, three days off is NOT as effective as daily ART: French study results need to be interpreted with caution

23 August 2019. Related: Conference reports, Treatment strategies.

Dolutegravir-based first-line non-inferior to efavirenz-based ART but associated with substantial weight gain: results from the ADVANCE study

23 August 2019. Related: Conference reports, Antiretrovirals, Treatment strategies, Side effects.

bNAb research at CROI 2019: vaccine, prevention, treatment and cure…

30 April 2019. Related: Conference reports, Treatment strategies, HIV prevention and transmission, Cure research.

Dolutegravir/3TC dual ART is as effective at lowest viral load cut-off as triple therapy in GEMINI studies

28 March 2019. Related: Conference reports, Antiretrovirals, Treatment strategies.

Same-day ART is effective in San Francisco Rapid-ART clinic

28 March 2019. Related: Conference reports, Antiretrovirals, Treatment strategies.

Viral reservoir can explain persistent low level viraemia with good adherence on ART

12 March 2019. Related: Conference reports, Treatment strategies.

Dolutegravir non-inferior to low dose efavirenz in real-life African study conducted in Cameroon

13 November 2018. Related: Conference reports, Antiretrovirals, Treatment strategies.

Dual bNAb maintains viral suppression for median 21 weeks off-ART

13 November 2018. Related: Conference reports, Antiretrovirals, Treatment strategies.

Dolutegravir monotherapy: still no longer recommended in either research or clinical practice

24 August 2018. Related: Conference reports, Treatment strategies.

Once-daily reduced dose darunavir/ritonavir (400 mg/100 mg) is non-inferior to twice-daily lopinavir/ritonavir in South African switch study

3 August 2018. Related: Conference reports, Treatment strategies.

M184V mutation associated with increased risk of viral blip but not viral failure with 3TC-based dual therapy

16 April 2018. Related: Conference reports, Treatment strategies, Resistance.

Early ART is not associated with a higher risk of HIV drug resistance

5 January 2018. Related: Treatment strategies, Resistance.

Dolutegravir-based dual therapy as switch option in multiple studies

28 November 2017. Related: Conference reports, Treatment strategies.

Switch study shows F/TAF non-inferior to continuing abacavir/3TC

28 November 2017. Related: Conference reports, Antiretrovirals, Treatment strategies.

Dolutegravir outperforms lopinavir/ritonavir second-line: interim results from the DAWNING study

10 August 2017. Related: Conference reports, Antiretrovirals, Treatment strategies, Treatment access.

Immune-based therapy canakinumab reduces inflammatory markers in HIV positive people on ART

24 April 2017. Related: Conference reports, Treatment strategies, Basic science and immunology.

Increased risk of IRIS with integrase inhibitors reported in two studies

24 April 2017. Related: Conference reports, Antiretrovirals, Treatment strategies, Coinfections and complications.

Dolutegravir monotherapy studies halted due to integrase resistance: dual therapy studies continue

27 February 2017. Related: Conference reports, Treatment strategies.

Simplifying HIV treatment: dual therapy works but monotherapy with either boosted-PIs or dolutegravir does not

29 November 2016. Related: Conference reports, Treatment strategies.

Atripla three days a week for two years: pilot switch study reports undetectable viral load with better bone, kidneys and sleep

1 October 2016. Related: Conference reports, Treatment strategies.

Four day a week ART: sub-optimal drug levels but few virological failures

1 October 2016. Related: Conference reports, Treatment strategies.

ZERO: no linked HIV transmissions in PARTNER study after couples had sex 58,000 times without condoms

1 August 2016. Related: Conference reports, Treatment strategies, HIV prevention and transmission.

CD4:CD8 ratio is more sensitive marker of risk than CD4 counts in analysis from START study

1 August 2016. Related: Conference reports, Treatment strategies.

Treatment in primary HIV infection is significantly more likely to normalise CD4:CD8 ratio

1 August 2016. Related: Conference reports, Treatment strategies.

Further results using dolutegravir monotherapy: urgent need for controlled studies

1 February 2016. Related: Antiretrovirals, Treatment strategies.

Potential economic impact of dolutegravir/3TC dual therapy

1 February 2016. Related: Antiretrovirals, Treatment strategies.

First-line ART with dolutegravir plus 3TC: 24-week early results

1 December 2015. Related: Conference reports, Antiretrovirals, Treatment strategies.

Achieving viral suppression with HIV multi-drug resistance: peg-interferon and valaciclovir as part of rescue therapy

1 December 2015. Related: Conference reports, Antiretrovirals, Treatment strategies, Resistance.

Four reasons IAS 2015 will be a milestone HIV conference: a personal view

1 August 2015. Related: Conference reports, Antiretrovirals, Treatment strategies, HIV prevention and transmission.

Starting HIV treatment at high CD4 counts protects against both AIDS and non-AIDS events: overall and in subgroup analyses of START study

1 August 2015. Related: Conference reports, Antiretrovirals, Treatment strategies.

The option for same day antiretroviral therapy on diagnosis: the future model for HIV care

1 August 2015. Related: Conference reports, Treatment strategies, Treatment access, Treatment advocacy, Other news.

Low dose boosted atazanavir is non-inferior to standard dose in Thai treatment optimisation study: LASA

1 August 2015. Related: Conference reports, Treatment strategies.

HPTN 052: no HIV transmissions on effective ART but only limited data on viral failure and drug resistance

1 August 2015. Related: Conference reports, Treatment strategies, HIV prevention and transmission.

Early HIV treatment and isoniazid prophylaxis: why TEMPRANO results do not yet support universal ART at CD4 counts >500

24 March 2015. Related: Conference reports, Treatment strategies, TB coinfection.

Weekend-off ART is non-inferior to continuous ART in young people taking efavirenz-based regimens: results from BREATHER study

24 March 2015. Related: Conference reports, Treatment strategies, Paediatric care.

Gender differences in use of cardiovascular disease-related interventions: D:A:D study

1 December 2014. Related: Conference reports, Treatment strategies, Women's health, Side effects.

Higher ART coverage is associated with lower HIV infection rates in a multi-country analysis

1 August 2014. Related: Conference reports, Treatment strategies, HIV prevention and transmission.

No difference in overall anaemia rate with reduced dose AZT

1 August 2014. Related: Conference reports, Treatment strategies, Treatment access.

Fit for purpose: treatment optimisation 2014

19 July 2014. Related: Pipeline report, Fit for purpose, Treatment strategies.

50% of UK seroconverters start ART within 1.4 years of infection: treating during primary infection should be a patient choice

27 May 2014. Related: Conference reports, Antiretrovirals, Treatment strategies.

PIVOT study: further analysis from five-year PI/r monotherapy strategy study

27 May 2014. Related: Conference reports, Antiretrovirals, Treatment strategies.

Hospitalisation among elite controllers

27 May 2014. Related: Conference reports, Treatment strategies.

Viral load rebound rate of 35% using ritonavir-boosted PI monotherapy: results of five-year PIVOT study

24 March 2014. Related: Conference reports, Antiretrovirals, Treatment strategies.

Dual therapy less effective at high viral load: NEAT 001 study with raltegravir/darunavir/r

24 March 2014. Related: Conference reports, Antiretrovirals, Treatment strategies.

Atazanavir, raltegravir and darunavir virologically equivalent in naive patients but significant differences for tolerability: results from ACTG 5257

24 March 2014. Related: Conference reports, Antiretrovirals, Treatment strategies.

NNRTI resistance found in 12% of people stopping treatment with undetectable viral load: implications for stock-outs

24 March 2014. Related: Conference reports, Treatment strategies, Resistance.

Southern African treatment guidelines retain CD4 threshold of 350 for starting ART (2013)

1 October 2013. Related: Treatment strategies, Treatment access, Guidelines.

Executive summary and research policy recommendations

30 June 2013. Related: Pipeline report, Antiretrovirals, Treatment strategies, Diagnostics, Hepatitis coinfection, TB coinfection.

Retrofitting for purpose: treatment optimisation 2013

30 June 2013. Related: Pipeline report, Fit for purpose, Treatment strategies.

The tuberculosis treatment pipeline

30 June 2013. Related: Pipeline report, Treatment strategies, TB coinfection.

Why the “when to start” question is complex and informed by limited evidence: a response to Dr Myron Cohen

1 April 2013. Related: Treatment strategies, Guidelines.

START study increases sample size: additional 600 participants to be older than 35

1 April 2013. Related: Antiretrovirals, Treatment strategies.

Treatment in seroconversion maintains HIV specific immune responses similar to long term slow progressors

1 August 2011. Related: Conference reports, Treatment strategies, Basic science and immunology.

Post navigation